MDR expression in normal tissues: Pharmacologic implications for the clinical use of P-glycoprotein inhibitors

Hematology/Oncology Clinics of North America

Volumn 9, Issue 2, 1995, Pages 319-336

  Lum, B L ^a   Gosland, M P ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOPERAZONE; CHLORPROMAZINE; COLCHICINE; CYCLOSPORIN A; CYTARABINE; CYTOCHROME P450; CYTOTOXIN; DAUNORUBICIN; DOXORUBICIN; DOXORUBICINOL; ETOPOSIDE; GENE PRODUCT; GLYCOPROTEIN P; IFOSFAMIDE; MITOXANTRONE; NIFEDIPINE; PACLITAXEL; PHENOTHIAZINE DERIVATIVE; PROGESTERONE; QUINIDINE; QUININE; TAMOXIFEN; VALSPODAR; VERAPAMIL; VINBLASTINE; VINCA ALKALOID; VINCRISTINE; VINDESINE;

ACUTE NONLYMPHOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG METABOLISM; DRUG MIXTURE; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MULTIDRUG RESISTANCE; NAUSEA; NEUROPATHY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RAT; REVIEW; VOMITING;

EID: 0028951303     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0889-8588(18)30097-2     Document Type: Review

References (63)

1. S. Altuvia W. Stein S. Goldenberg Targeted disruption of the mouse mdr1b gene reveals that steroid hormones enhance mdr gene expression J Biol Chem 268 1993 27127 27132
2. R. Arceci F. Baas R. Raponi Multidrug resistance gene expression is controlled by steroid hormones in the secretory epithelium of the uterus Mol Reprod Dev 25 1990 101 109
3. N. Bartlett B.L. Lum G.A. Fisher A Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance J Clin Oncol 12 1994 835 842
4. K. Becker H. Allmeir V. Holt New mechanisms of hormone secretion: MDR-like gene products as extrusion pumps for hormones? Horm Metab Res 24 1992 210 213
5. K. Burt S. Thorgeirson Coinduction of MDR1 multidrug resistance and cytochrome P450 genes in rat liver by xenobiotics J Natl Cancer Inst 80 1988 1383 1386
6. N.J. Chao M. Aihara K.G. Blume Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow Exp Hematol 18 1990 1193 1198
7. P. Chaudhary I. Roninson Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells Cell 56 1991 85 94
8. A. Chong P. Markham H. Gebel Diverse multidrug-resistance modification agents inhibit cytolytic activity of natural killer cells Cancer Immunol Immunother 36 1993 133 139
9. R. Christen F. McClay S. Plaxe Phase I/pharmacokinetic study of high-dose progesterone and doxorubicin J Clin Oncol 11 1993 2417 2426
10. C. Cordon-Cardo J. O’Brien J. Boccia Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38 1990 1277 1287
11. T. Cresteil B. Monsarrat P. Alvinerie Taxol metabolism by human liver microsomes: Identification of cytocrome P450 isozymes involved in its biotransformation Cancer Res 54 1994 386 392
12. D. Drach S. Zhao J. Drach Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistance gene Blood 80 1992 2729 2734
13. A. Dutt T. Priebe L. Teeter Postnatal development of organic cation transport and mdr gene expression in mouse kidney J Pharmacol Exp Ther 261 1992 1222 1230
14. C. Erlichman M. Moore J. Thiessen A Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin Cancer Res 53 1993 4837 4842
15. C. Erlichman M. Moore J. Thiessen A phase I trial of doxorubicin and PSC833, a modulator of multidrug resistance Proc Am Soc Clin Oncol 13 1994 134
16. L. Fedeli M. Colozza E. Boschetti Pharmacokinetics of vincristine in cancer patients treated with nifedipine Cancer 64 1989 1805 1811
17. R.L. Fine S. Koizumi G.A. Curt Effect of calcium channel blockers on human CFUGM with cytotoxic drugs J Clin Oncol 5 1987 489 495
18. G.A. Fisher J. Hausdorf B.L. Lum Phase I trial of etoposide with the cyclosporin SDZ PSC 833, a modulator of multidrug resistance Proc Am Soc Clin Oncol 13 1994 143
19. G.A. Fisher N.L. Bartlett B.L. Lum Phase I trial of taxol with high dose cyclosporine as a modulator of multidrug resistance Proc Am Soc Clin Oncol 13 1994 144
20. F. Formelli L. Cleris R. Carsana Effect of verapamil on doxorubicin activity and pharmacokinetics in mice bearing resistant and sensitive solid tumors Cancer Chemother Pharmacol 21 1988 329 336
21. Z. Gatmaitan I. Arias Structure and function of P-glycoprotein in normal liver and small intestine Adv Pharmacol 24 1993 77 96
22. P. Genne M.T. Dimanche-Boitrel R.Y. Mauvernay Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance in vivo Cancer Res 52 1992 2797 2801
23. G. Giaccone S.C. Linn G. Catimel Phase I and pharmacokinetic study of SDZ PSC 833 per os in combination with doxorubicin in patients with solid tumors Proc Am Soc Clin Oncol 13 1994 142
24. M. Gosland N. Brophy G. Duran Bilirubin., A physiological substrate for the multidrug transporter Proc Am Assoc Cancer Res 32 1991 426
25. M. Gosland C. Tsuboi T. Hoffman 17β-etradiol glucuronide: An inducer of cholestasis and a physiological substrate for the multidrug resistance transporter Cancer Res 53 1993 5382 5385
26. S. Gupta S. Gollapudi P-glycoprotein (MDR 1 gene product) in cells of the immune system: Its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection J Clin Immunol 13 1993 289 301
27. E. Hegmann H. Bauer R. Kerbel Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells Cancer Res 52 1992 6969 6975
28. J.K. Horton N. Kuntebommanahalli K.N. Thimmaiah Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts Biochem Pharmacol 38 1989 1727 1736
29. D.J. Kerr J. Graham J. Cummings The effect of verapamil on the pharmacokinetics of Adriamycin Cancer Chemother Pharmacol 18 1986 239 242
30. C. Le Guellec B. Lacarelle J. Catalin Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes Cancer Chemother Pharmacol 32 1993 491 495
31. A.F. List C. Speir J. Geer Phase I/II trial of cyclosporine as a chemotherapyresistance modifier in acute leukemia J Clin Oncol 11 1993 1652 1660
32. B.L. Lum S. Kaubisch A.M. Yahanda Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporin in a phase I trial to modulate multidrug resistance J Clin Oncol 10 1992 1635 1642
33. B.L. Lum S. Kaubisch K.M. Adler Enhanced leukopenia by cyclosporine in a phase I trial of modulation of etoposide resistance: Pharmacokinetic and pharmacodynamic analysis Proc Am Assoc Cancer Res 33 1992 236
34. B.L. Lum M.P. Gosland S. Kaubisch Molecular targets in oncology: Implications of the multidrug resistance gene Pharmacotherapy 13 1993 88 109
35. B.L. Lum A.M. Yahanda G.A. Fisher Modulation of etoposide multidrug resistance with cyclosporine: Pharmacokinetic and pharmacodynamic considerations in the development of clinical trials Cancer 72 1993 3502 3514
36. J.-P. Marie J.-N. Bastie F. Coloma Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL) Leukemia 7 1993 821 824
37. J. Mason R. Christen S. Mullen Progesterone enhances doxorubicin induced toxicity in human hematopoietic progenitor cells Proc Am Soc Clin Oncol 13 1994 156
38. K. Mewes J. Blanz G. Ehninger Cytocrome P-450-induced cytotoxicity of mitoxantrone by formation of electrophilic intermediates Cancer Res 53 1993 5135 5142
39. M.J. Millward B.M.J. Cantwell N.C. Munro Oral verapamil with chemotherapy for advanced non-small cell lung cancer: A randomized study Br J Cancer 67 1993 1031 1035
40. K. Mross K. Hamm D.K. Hossfeld Effects of verapamil on the pharmacokinetics and metabolism of epirubicin Cancer Chemother Pharmacol 31 1993 369 375
41. K. Nooter R. Oostrum J. Deurloo Effects of verapamil on the pharmacokinetics of daunomycin in the rat Cancer Chemother Pharmacol 20 1987 176 178
42. I. Pastan M.M. Gottesman Multi-drug resistance in human cancer N Engl J Med 316 1987 1388 1393
43. P. Philip S. Joel S. Monkman A phase I study on the reversal of multidrug resistance (MDR) in-vivo: Nifedipine plus etoposide Br J Cancer 65 1992 267 270
44. M.V. Relling W.E. Evans R. Fonne-Pfister Anticancer drugs as inhibitors of two polymorphic cytochrome P450 enzymes, debrisoquin and mephytoin hydroxylase, in human liver microsomes Cancer Res 49 1989 68 71
45. M.V. Relling R. Evans C. Dass Human cytochrome P450 metabolism of teniposide and etoposide J Pharmacol Exp Ther 261 1992 491 496
46. B. Samuels R. Mick N. Vogelsang Modulation of vinblastine resistance with cyclosporine: A Phase I study Clin Pharmacol Ther 54 1993 421 429
47. D. Schrenk T.W. Gant K.-H. Preisegger Induction of multidrug resistance gene expression during cholestasis in rats and nonhuman primates Hepatology 17 1993 854 860
48. M.A. Smith S. Merry J.G. Smith Clinically relevant concentrations of verapamil do not enhance the sensitivity of human bone marrow CFU-GM to Adriamycin and VP16 Br J Cancer 57 1988 576 578
49. E. Solary D. Caillot B. Chauffert Feasibility of using quinine, a potential resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia J Clin Oncol 10 1992 1730 1736
50. K. Speeg A. Malonado J. Liaci Effect of cyclosporine on colchicine secretion by the kidney multidrug transporter studied in vivo J Pharmacol Exp Ther 261 1992 750 755
51. K. Speeg A. Maldonado J. Liaci Effect of cyclosporine on colchicine secretion by a liver canalicular transporter studied in vivo Hepatology 15 1992 899 903
52. N.S.A. Stuart P. Philip A.L. Harris High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines Br J Cancer 66 1992 833 839
53. F. Thiebaut T. Tsuruo H. Hamada Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues Proc Natl Acad Sci USA 84 1987 7735 7739
54. S.S. Thorgierrson J.A. Silverman T.W. Gant Multidrug resistance gene family and chemical carcinogenesis Pharmacol Ther 49 1991 283 292
55. A.W. Tolcher K.H. Cowan D. Solomon A phase I study of paclitaxel with Rverapamil in metastatic breast cancer Proc Am Soc Clin Oncol 13 1994 139
56. D.L. Trump D.C. Smith P.G. Ellis High-dose oral tamoxifen, a potential multidrugresistance-reversal agent: Phase I trial in combination with vinblastine J Natl Cancer Inst 84 1992 1811 1816
57. K. Veda N. Okamura M. Hira Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone but not progesterone J Biol Chem 267 1992 24248 24252
58. M. Vore M. Gosland C. Tsuboi T. Hoffman Cholestatic steroid glucuronides: Interactions with P-glycoprotein (P-gp) Hepatology 18 1993 139A
59. R. Weinstein J. Kuszak L. Kluskens P-glycoproteins in pathology: The multidrug resistance gene family in humans Hum Pathol 21 1990 34 46
60. A.M. Yahanda K.M. Adler G.A. Fisher A phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance J Clin Oncol 10 1992 1624 1634
61. J.C. Yalowich J.R. Zucali M. Gross Effects of verapamil on etoposide, vincristine, and Adriamycin activity in normal human bone marrow granulocyte-macrophage progenitors and in human K562 leukemia cells in vitro Cancer Res 45 1985 4921 4924
62. P. Young P. Kransey Stimulation of interleukin lβ secretion in monkey kidney cells by coexpression of the mammalian P-glycoprotein MDR 1 P. Ghezzi A. Mantovani Pathophysiology and Pharmacology of Cytokines 1992 Biomedical Press Boca Raton, FL 21 27
63. X.-R. Zhou-Pan E. Seree Zhou X-J, et al., Involvement of human liver cytochrome P450 3A in vinblastine metabolism: Drug interactions Cancer Res 53 1993 5121 5126